The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial
Table 2
Results after 18 months of treatment.
Daily clinical practice group ()
RCT group ()
Delta
value
BMI (kg/m2)
31.0 (27.9–32.8)
30.5 (26.0–32.4)
−0.36 (−2.10–1.58)
29.8 (28.1–34.5)
29.9 (26.3–33.6)
0.22 (−2.87–1.27)
0.686
BMI-SDS
3.23 (3.05–3.64)
3.00 (2.43–3.37)
−0.15 (−0.54–0.05)
3.10 (2.72–3.52)
2.90 (2.34–3.39)
−0.12 (−0.50–0.08)
0.990
FPG (mmol/l)
5.0 (4.8–5.6)
5.4 (5.0–5.7)a
0.2 (0.0–0.3)a
4.8 (4.7–5.0)
4.6 (4.4–4.8)
−0.2 (−0.5–0.0)
0.001
FPI (μU/ml)
31.0 (21.0–41.9)
19.6 (11.0–34.0)a
−5.0 (−20.5–6.3)a
18.0 (11.0–27.0)
15.0 (10.0–20.0)
−3.0 (−13.0–6.0)
0.661
HOMA-IR
7.16 (4.31–8.96)
4.29 (2.52–9.43)a
−1.03 (−4.48–1.88)a
4.00 (2.30–6.36)
3.00 (2.00–4.29)
−1.00 (−3.17–1.47)
0.802
HbA1c
34 (32–39)a
34 (33–36)a
−1.0 (−3.5–3.5)b
33 (31–34)
34 (31–34)c
1.0 (−1.0–2.3)c
0.480
Data are presented as median (interquartile range). ; ; . BMI (SDS): body mass index (standard deviation score); FPG: fasted plasma glucose; FPI: fasted plasma insulin; HOMA-IR: homeostasis model assessment for insulin resistance.
